Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.

Voysey M. et al, (2023), Clin Exp Immunol

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021), Nature Medicine

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.

Swanson PA. et al, (2021), Sci Transl Med, 13

Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction

Ratcliff J. et al, (2021)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Divergent trajectories of antiviral memory after SARS-Cov-2 infection

Tomic* A. et al, (2021)

Antibody evasion by the P.1 strain of SARS-CoV-2.

Dejnirattisai W. et al, (2021), Cell, 184, 2939 - 2954.e9

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.

Townsend A. et al, (2021), Nat Commun, 12

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Emary KRW. et al, (2021), SSRN Electronic Journal

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Voysey M. et al, (2021), The Lancet

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers

Barton A. et al, (2021)

SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus.

Andersson MI. et al, (2020), Wellcome open research, 5, 181 - 181

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.

Folegatti PM. et al, (2020), Lancet, 396, 467 - 478

Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel.

Ainsworth M. et al, (2020), Wellcome open research, 5, 139 - 139

SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus

Andersson MI. et al, (2020)

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.

Valente Pinto M. et al, (2020), 7

Include forthcoming?